Calcium Channel Blockers as Contributing Factors to Nocturia

Guideline Recognition

The 2022 European Urology guidelines list calcium‑channel blockers (CCBs) among the medications that must be reviewed when evaluating nocturia, placing them in the same risk category as diuretics, lithium and NSAIDs (strong recommendation). 1
The 2022 PLANET study guidance similarly recommends that CCBs be considered during the initial nocturia assessment (strong recommendation). 2

CCBs are thought to cause peripheral edema during daytime; when the patient lies down, fluid redistributes to the central circulation, producing nocturnal polyuria. Consequently, the guidelines advise routine screening for ankle swelling as part of nocturia work‑up (moderate recommendation). 3

Peripheral edema check – Examine the lower extremities for edema when assessing nocturia. 4
Bladder diary – Obtain a 72‑hour bladder diary to quantify nocturnal urine volume and frequency. 5
Medication timing review – Evaluate the timing of amlodipine (or other CCB) dosing relative to bedtime, because dosing time can affect nocturnal symptoms (moderate recommendation). 8
Quality‑of‑life assessment – Measure the impact of nocturia on quality of life and daytime function to set treatment thresholds (moderate recommendation). 6

Adjust CCB dosing time – Modify the timing of calcium‑channel blocker administration, taking into account the drug’s duration of effect and the patient’s usual bedtime, to lessen nocturnal symptoms (moderate recommendation). 9

Nocturia is often multifactorial, especially in older adults; clinicians should also evaluate other common contributors such as benign prostatic hyperplasia, sleep disorders, and alternative sources of nocturnal polyuria. 10
A clear improvement in nocturia after adjusting or discontinuing the CCB is required to confirm a causal relationship with amlodipine. 8